Please note that a publication can be assigned to several endpoints, i.e. the sum of publications from the individual thematic points and subpoints can be greater than the total sum of actual publications.
Authors | Year | Exposed system | Parameters | Magnetic flux density/field strength |
---|---|---|---|---|
Zhang K et al. | 2014 | intact cell/cell culture, K562 cells (human erythroleukemic cell line) | static magnetic field, DC, co-exposure | 8.8 mT |
Pacini S et al. | 1999 | intact cell/cell culture, MCF-7 (human breast cancer cell line) | static magnetic field, MRI, co-exposure | 200 mT |
Reddig A et al. | 2015 | intact cell/cell culture, human lymphocytes | static magnetic field, MRI, co-exposure | - |
Letuta UG et al. | 2017 | bacterium, <i>Escherichia coli</i> | static magnetic field, also other exposures without EMF, co-exposure | - |
Jalali A et al. | 2019 | intact cell/cell culture, A2780 (human ovarian carcinoma-sensitive to cisplatin) and A2780-CP (human ovarian carcinoma-resistant to cisplatin) | static magnetic field, also other exposures without EMF, co-exposure | - |
Vergallo C et al. | 2020 | intact cell/cell culture, human peripheral blood mononuclear cells | static magnetic field, also other exposures without EMF, co-exposure | - |
Kimsa-Dudek M et al. | 2020 | intact cell/cell culture, C32 cells (human melanoma cell line) and, C32 cells (human melanoma cell line) and NHDF cells (normal human dermal fibroblasts) | static magnetic field, also other exposures without EMF, co-exposure | - |
Satari M et al. | 2021 | intact cell/cell culture, HeLa cell line (human adenocarcinoma cell line) and Huo2 cells (skin fibroblast cells) | static magnetic field, also other exposures without EMF, co-exposure | - |
Kerschbaum-Gruber S et al. | 2022 | intact cell/cell culture | static magnetic field, also other exposures without EMF, co-exposure | - |
Guo S et al. | 2023 | intact cell/cell culture, human periodontal ligament stem cells | static magnetic field, also other exposures without EMF, co-exposure | - |
This website uses cookies to provide you the best browsing experience. By continuing to use this website you accept our use of cookies.